Filing Summary
Entity and period: The supplied filing is a Form 10-Q for Reneo Pharmaceuticals, Inc., not OnKure Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2023, and was filed November 13, 2023. Reneo is a clinical-stage pharmaceutical company developing mavodelpar (REN001) for rare genetic mitochondrial diseases.
Business Context and Development Status
- Mavodelpar is the company’s only product candidate and is being developed for primary mitochondrial myopathies (PMM) and selected long-chain fatty acid oxidation disorders (LC-FAOD).
- The pivotal Phase 2b STRIDE study enrolled 213 patients, above the 200-patient target, in March 2023. Topline data were expected in December 2023.
- Management anticipated a potential U.S. NDA submission for PMM in the first half of 2024 and a European MAA submission in late 2024, subject to positive clinical results and regulatory review.
- The company had 55 employees as of September 30, 2023, and had not generated product revenue.
Financial Results and Key Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Research and development expense | $13.6 million | $9.9 million | $39.0 million | $27.3 million |
| General and administrative expense | $7.3 million | $3.9 million | $19.0 million | $11.9 million |
| Total operating expenses | $20.9 million | $13.8 million | $58.0 million | $39.3 million |
| Other income | $1.7 million | $0.8 million | $4.2 million | $0.9 million |
| Net loss | $19.2 million | $13.0 million | $53.8 million | $38.4 million |
| Basic and diluted loss per share | $0.57 | $0.53 | $1.81 | $1.57 |
| Net cash used in operating activities | Not provided for quarter | Not provided for quarter | $43.9 million | $31.7 million |
The company reported no revenue, operating margins were negative, and it remained unprofitable. The nine-month net loss increased by $15.5 million, or approximately 40%, year over year.
Balance Sheet, Liquidity, and Capitalization
- Cash and cash equivalents were $11.7 million at September 30, 2023, compared with $19.9 million at December 31, 2022.
- Short-term investments were $113.9 million, compared with $81.2 million at year-end 2022.
- Total cash, cash equivalents, and short-term investments were approximately $125.6 million.
- Total liabilities were $15.4 million, including $13.6 million of current liabilities. The filing reports no debt financing outstanding; lease liabilities totaled approximately $1.1 million.
- Accumulated deficit was $190.5 million, compared with $136.7 million at December 31, 2022.
- Net cash used in investing activities was $29.3 million, primarily reflecting purchases of short-term investments.
- Net cash provided by financing activities was $65.0 million, mainly from equity offerings.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $3.7 million in Q3 and $11.7 million for the nine-month period, primarily due to clinical development, contract manufacturing, personnel, and medical affairs costs.
- General and administrative expense increased $3.4 million in Q3 and $7.1 million for the nine-month period, driven by commercial development, facility, and personnel expenses.
- Higher interest income increased other income by $0.9 million in Q3 and $3.3 million for the nine-month period.
- Cash used in operations increased $12.2 million to $43.9 million for the nine-month period.
- In May 2023, Reneo raised approximately $58.9 million net in a public offering and approximately $4.7 million net in a concurrent private placement, issuing 8,531,250 shares in total.
- Shares issued and outstanding increased to 33.9 million at September 30, 2023 from 24.7 million at December 31, 2022, creating substantial equity dilution.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that available liquidity was expected to fund operations through a potential PMM NDA submission in the first half of 2024, but not for more than one year from the filing date because of anticipated increases in commercial development spending.
- Management concluded that substantial doubt exists regarding the company’s ability to continue as a going concern. Planned remedies include additional equity or debt financing, collaborations, licensing transactions, and deferral of certain commercial activities.
- On November 13, 2023, the company entered into a new $100.0 million ATM facility. No shares had been sold under it as of the filing date. The prior $20.0 million ATM facility was terminated.
- On October 30, 2023, the company repurchased and retired 576,443 shares from vTv Therapeutics for approximately $4.4 million.
- The vTv license agreement includes up to $64.5 million of development and regulatory milestones, up to $30.0 million of sales-based milestones, and tiered royalties. Reneo had paid $2.0 million of development and regulatory milestones through September 30, 2023.
- A $7.5 million CEO performance award is payable in cash, stock, or a combination if specified market-value or change-in-control conditions are achieved. Its recorded fair value was $1.1 million at September 30, 2023.
- Key risks include failure of the STRIDE trial, regulatory delays or rejection, limited patient populations, reliance on third-party manufacturers and CROs, single-product concentration, intellectual-property challenges, additional financing needs, dilution, and inability to establish commercial capabilities.
- The company disclosed no material legal proceedings and concluded that disclosure controls and procedures were effective as of September 30, 2023.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Reneo Pharmaceuticals, Inc. and ticker RPHM, not OnKure Therapeutics, Inc.
- Verify the December 2023 STRIDE topline data and whether the results support the anticipated 2024 NDA submission.
- Monitor cash burn, commercial development spending, and the timing and terms of additional financing given the disclosed going-concern uncertainty.
- Assess dilution from the $100.0 million ATM facility, equity compensation, and any future financings.
- Review regulatory, manufacturing, licensing, and intellectual-property developments affecting mavodelpar.